CURRENT EVIDENCE-BASED KNOWLEDGE FOR DIAGNOSIS AND MANAGEMENT REFRACTORY OVERACTIVE BLADDER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Increasing number of patients with overactive bladder was observed over the past few years. The prevalence of OAB rises with age, and significantly affects the patients' quality of life. Large-scale epidemiological studies have reported on the prevalence of AOB, which was 15—20% in adult women and about 6% in younger women (15— 20 years old). The evidence of infectious nature of AOB is cumulated last years. Many manuals and guidelines, like NICE, recommend screening for uncomplicated urinary tract infections in patients with AOB and administer antimicrobial therapy when it's revealed. Deficiency in this glycosaminoglycan layer of the bladder is thought to be one of the main cause of cystitis recurring why is the researches on replacement therapy with hyaluronic acid were conducted. It is known that some cytokines and urinary nerve growth factor, detected in the urinary, are biomarkers for inflammatory, and correlate with intensity of urgency. However, all currently known biomarkers demand further investigations, prognostic value and their role in clinical practice assessment.

Full Text

Restricted Access

About the authors

T. A TETERINA

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: palpebra@inbox.ru
Moscow, Russia

F. N MAKHMEDZHANOVA

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: f_makhmed@mail.ru
Moscow, Russia

I. A APOLIKHINA

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow Medical State University

Email: apolikhina@inbox.ru
Moscow, Russia

P. V GLYBOCHKO

I.M. Sechenov First Moscow Medical State University

Moscow, Russia

References

  1. Глыбочко П.В., Аляев Ю.Г., Гаджиева З.К., Локшин К.Л., Миркин Я.Б. Применение гиалуроновой кислоты в лечение хронического цистита. Эффективная фармакотерапия. Урология. 2011; 5: 30-5.
  2. Ибинаева И.С. Научное обоснование разработки алгоритма ведения женщин с недержанием мочи: Автореф. дис.. канд. мед. наук. М.; 2012. 48 с.
  3. Лесовой В.Н., Гарагатый И.А., Колупаев С.М., Колупаева Л.С. Диагностическое значение определения уровня провоспалительных цитокинов в моче больных гиперактивным мочевым пузырем. Экспериментальная и клиническая медицина. 2011; 2: 159-61.
  4. Липова Е.В. Анатомо-физиологические особенности мочеполовой системы женщины (учебное пособие). М.; 2000: 12-4.
  5. Набока Ю.Л., Коган М.И., Васильева Л.И., Губима И.А., Мирошниченко Е.А., Ибишев Х.С. Бактериальная микст-инфекция у женщин с хроническим рецидивирующим циститом. Журнал микробиологии, эпидемиологии и иммунобиологии. 2011; 1: 8-12.
  6. Abrams P., Cardozo L., Khoury S., Wein A., eds. Incontinence: 3rd International consultation on incontinence. vol. 1-2. Paris: Health Publication Ltd.; 2005.
  7. Apodaca G. The uroepithelium: not just a passive barrier. Traffic. 2004; 5(3): 117-28.
  8. Cartwright R., Afshan I., Derpapas A., Vijaya G, Khullar V. Novel biomarkers for overactive bladder (review). Nat. Rev. Urol. 2011; 8(3): 139-45.
  9. Cohen B.L., Barboglio P., Gousse A. The impact of lower urinary tract symptoms and urinary incontinence of female sexual dysfunction using a validated instrument. J. Sex. Med. 2008; 5(6): 1418-23.
  10. Coyne K.S., Margolis M.K., Jumadilova Z., Bavendam T., Mueller E., Rogers R. Overactive bladder and women’s sexual health: what is the impact? J. Sex. Med. 2007; 4(3): 656-66.
  11. Eto D.S., Sunsdsbak J.L., Mulvey M.A. Actin - gated intracellular growth and resurgence of uropathogenic Escherichia coli. Cell. Microbiol. 2006; 8(4): 704-17.
  12. Furtado D., Hachul H., Andersen M.L., Castro R.A., Girao M.B., Tufik S. Nocturia and disturbed sleep: a review. Int. Urogynecol. J. 2012; 23(3): 255-67.
  13. Gill K., Kupelian A.S., Brackenridge L. et al. Symptoms most sensitive to urinary tract infection. Int. Urogynecol. J. 2011; 22: 271-2.
  14. Graham E., Chai T.C. Dysfunction of bladder urothelium and bladder urothelial cells in inrestitial cystitis. Curr. Urol. Rep. 2006; 7(6): 440-6.
  15. Gupta K., Hooton T.M., Wobbe C.L., Stamm W.E. The prevalence of antimicrobial resistance among uropathogenes causing acute uncomplicated cystitis in young women. Int. J. Antimicrob. Agents. 1999; 11(3-4): 305-8.
  16. Hanno P.M., Malkowicz S.B., Wein A.J. Penn clinical manual of urology. Philadelphia: Saunders Elsevier; 2007: 155-75.
  17. Haylen B.T., de Ridder D., Freeman R.M., Swift S.E., Berghmans B., Lee J. et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol. Urodyn. 2010; 29(1): 4-20.
  18. Hessdoerfer E., Jundt K., Peschers U. Is a dipstick test sufficient to exclude urinary tract infection in women with overactive bladder? Int. Urogynecol. J. 2011; 22(2): 229-32.
  19. Ingersoll M.A., Kline K.A., Nielsen H.V., Hultgren S.J. G-CSF induction early in uropathogenic E.coli infection of the urinary tract modulates host immunity. Cell. Microbiol. 2008; 10: 2568-78.
  20. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S. еt al. Population - based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of EPIC study. Eur. Urol. 2006; 50(6): 1306-14.
  21. Janeway C., Travers P., Walport M., Shlomchik M. Immunobiology: The immune system in health and disease. 6th ed. New York: Garland Science; 2005.
  22. Jiann B.P., Su C.C., Yu C.C., Wu T.T., Huang J.K. Risk factors for individual domains of female sexual function. J. Sex. Med. 2009; 6(12): 3364-75.
  23. Katchman E.A., Milo G., Paul M., Christiaens T., Baerheim A., Leibovici L. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and metaanalysis. Am. J. Med. 2005; 118(11): 1196-207.
  24. Kerrn M.B., Struve C., Blom J., Frimodt-M0ller N., Krogfelt K.A. Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice. J. Antimicrob. Chemother. 2005; 55(3): 383-6.
  25. Khasriya R.K., Ismail S., Wilson M., Malone-Lee J. Caught inflagrante - pathogens from OAB patients observed as they invade urothelial cell lines. Int. Urogynecol. J. 2011; 22 (Suppl. 1): 193-4.
  26. Kim J.C., Park E.Y., Seo S.I., Park Y.H., Hwang T.K. Nerve growth factor and prostaglandins in the urine of female patient with overactive bladder. J. Urol. 2006; 175(5): 1773-6.
  27. Kim Y.K., Seo J.T., Yoon H. The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle - aged women. Int. J. Impot. Res. 2005; 17(2): 158-63.
  28. Kuo H.-C., Liu H.-T., Chancellor M.B. Can urinary nerve growth factor Be a biomarker for overactive bladder? Rev. Urol. 2010; 12(2-3): e69-e77.
  29. Kupelian A.S., Chalina C., Gill K. et al. Pain symptoms as part of the OAB complex. Int. Urogynecol. J. 2011; 22.
  30. Lapitan M.C., Chye P.L.; Asia-Pacific Continence Advisory Board. The epidemiology of overactive bladder among females in Asia: a questionnaire survey. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2001; 12(4): 226-31.
  31. Lipovac M., Kurz C., Reithmayr F., Verhoeven H.C., Huber J.C., Imhof M. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int. J. Gynaecol. Obstet. 2007; 96(3): 192-5.
  32. Liu H.T., Chen C.Y., Kuo H.C. Urinary nerve growth factor in women with overactive bladder syndrome. Br. J. Urol. Int. 2010; 107: 799-803.
  33. Liu H.T., Lin H., Kuo H.C. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol. Urodyn. 2011; 30(8): 1525-9.
  34. Melville J.L., Delaney K., Newton K., Katon W. Incontinence severity and major depression in incontinent women. Obstet. Gynecol. 2005; 106: 585-92.
  35. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population - based prevalence study. Br. J. Urol. Int. 2001; 87(9): 760-6.
  36. National Institute for Health and Clinical Excellence. Urinary incontinence: the management of urinary incontinence in women. NICE Guideline CD40; 2006.
  37. Ochodnicky P., Cruz C.D., Yoshimura N., Michel M.C. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target (review). Neurourol. Urodyn. 2011; 30(7): 1227-41.
  38. Pakiz M., Blazevic S., But I. The prevalence and risk factors for OAB in adolescent girls. In: Materials of ICS/IUGA Annual Meeting. Toronto, 23-23 August, 2010: abstr.23.
  39. Parsons C.L. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/ prostatitis/ urethritis. Urology. 2007; 69: 9-16.
  40. Rodhe N., Englund L., Mölstad S., Samuelsson E. Bacteriuria is associated with urge urinary incontinence in older women. Scand. J. Primary Health Care. 2008; 26(1): 35-9.
  41. Saini R., Gonzalez R.R., Te A.E. Chronic pelvic pain and the overactive bladder: the inflammatory link. Curr. Opin. Urol. 2008; 9: 314-9.
  42. Sako T., Inoue M., Watanabe T., Ishii A., Yokoyama T., Kumon H. Impact of overactive bladder and lower urinary tract symptoms on sexual health in Japanese women. Int. Urogynecol. J. 2011; 22(2): 165-9.
  43. Sathiananthamoorthy S., Khasriya R., Kupelian A.S., Gill K., Malone-Lee J. Improving the diagnosis of urinary tract infection - urothelial cell cediment concentrates cultured on chromogenic agar. Int. Urogynecol. J. 2011; 22(Suppl.).
  44. Schnegelsberg B., Sun T.T., Cain G., Bhattacharya A., Nunn P.A., Ford A.P. et al. Overexpression og NGF in mouse urothelium leads to hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 298(3): 534-47.
  45. Sivick K.E., Mobley H.L. Waging war against uropathogenic Escherichia coli: winning back the urinary tract (minireview). Infect. Immun. 2010; 78(2): 568-85.
  46. Smaldone M.C., Vodovotz Y., Tyagi V., Barclay D., Philips B.J., Yoshimura N. et al. Multiplex analysis of urine cytokine levels in a rat model of cyclophosphamid - indused cystitis. Urology. 2009; 73(2): 421-6.
  47. Staskin D., Hilton P., Emmanuel A., Goode P., Mills I., Shull B. et al. Initial assessment of incontinence. In: Abrams P., Cardozo L., Khoury S., Wein A., eds. Incontinence: 3rd International consultation on incontinence. Plymouth, Mass: Health Publication Ltd.; 2005. vol.1: 485-518.
  48. Steers W.D., Kolbeck S., Creedon D., Tuttle J.B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and functions. J. Clin. Invest. 1991; 88: 1709-15.
  49. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003; 21(6): 327-36.
  50. Tikkinen K.A., Johnson T.M. 2nd, Tammela T.L., Sintonen H., Haukka J., Huhtala H., Auvinen A. Nocturia frequency, bother and quality of life: how often is too often? A population-based study in Finland. Eur. Urol. 2009; 57(3): 488-96.
  51. Tyagi P. Pathophysiology of the urothelium and detrusor. Can. Urol. Assoc. J. 2011; 5(Suppl. 2): S128-30.
  52. Vijaya G., Cartwright R., Digesu G. et al. Can urinary nerve growth factor (NGF) replace urodynamics to diagnose lower urinary tract symptoms. Int. Urogynecol. J. 2011; 22 (Suppl. 1): 20-1.
  53. Walsh C.A., Siddins A., Parkin K., Mukerjee C., Moore K.H. Prevalence of «low-count» bacteriuria in female urinary incontinence versus continent female controls: a crosssectional study. Int. Urogynecol. J. 2011; 22(10): 1267-72.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies